Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025.

Edwards Lifesciences (NYSE:EW) reported fourth-quarter and full-year 2025 results that management characterized as strong, ...

Edwards Lifesciences (NYSE:EW) develops medical devices for structural heart disease, transcatheter procedures, and critical care, highlighting operational performance in the NYSE Composite sector.

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study results with driving a “sense of urgency” for treating patients.

Edwards Lifesciences guidance update highlights structural heart technology activity within the s&p 500, covering earnings ...

The Global Tricuspid Valve Repair Market is expected to reach a US$2.5 billion market by 2028. Rise in the incidence of ...

Edwards Lifesciences Corporation (NYSE:EW) Q4 2025 Earnings Call Transcript February 10, 2026 Edwards Lifesciences ...

Feb 10 (Reuters) - Edwards Lifesciences on Tuesday forecast 2026 profit above estimates, betting on robust demand for its artificial heart valves and other medical devices, sending its shares up 3% in ...

Investors reacted positively to Edwards’ 2026 guidance with shares up 1.25% in after-hours trading following the announcement.

Edwards Lifesciences reports strong Q4 2025 results with 13.3% sales growth to $1.57B, driven by TAVR and TMTT performance ...

Just after the close of regular trading, Edwards Lifesciences released fourth quarter and full year 2025 financial results. During today's call, management will discuss the results included in the ...

Detailed price information for Edwards Lifesciences Corp (EW-N) from The Globe and Mail including charting and trades.